Providing independent clinical excellence since 2005
Prediabetes should be viewed as an active cardiometabolic disease stage rather than a passive risk marker. Cardiovascular injury begins before overt diabetes, creating a critical window for intervention. Lifestyle therapy remains fundamental, while agents such as metformin, GLP-1 receptor agonists, dual incretin therapies, and SGLT2 inhibitors may help modify long-term cardiovascular risk.
Because cholesterol is a fat-like substance, it cannot dissolve or travel freely in blood, which is mostly water. To move around, it must be packaged into microscopic transport particles called lipoproteins. One of these, LDL (low-density lipoprotein), acts as the main delivery vehicle, carrying cholesterol from the liver to cells that need it for repair or hormone production. In small amounts, LDL cholesterol is therefore completely normal and necessary. The problem only begins when too much LDL remains circulating in the blood for too long.
Cardiometabolic risk develops gradually through visceral fat accumulation, insulin resistance and rising blood pressure. A structured escalation model — from supported self-management to specialist review and selective GLP-1 therapy — allows proportionate intervention before overt cardiovascular disease emerges. Early, coordinated action can alter long-term risk trajectories.
An article by Dr Edward Leatham, Consultant Cardiologist © 2025 E. Leatham This article explores carbohydrates, visceral fat (VAT), and why adding fats to food may lower your cardiometabolic risk. Short on time? Listen to the 15-minute VAT-Trap podcast summary […]
January isn’t just about weight loss. Much winter weight gain occurs as visceral fat, which drives insulin resistance and cardiovascular risk. Measuring your waist, not just your weight, gives a clearer picture of metabolic health. Building muscle and reducing visceral fat supports a healthier metabolism long after January ends.
The Eight-Month Metabolic Reset is a structured cardiometabolic programme designed to reduce visceral fat, preserve skeletal muscle strength, and improve glucose stability. Combining lifestyle change, targeted metabolic support, and clinical guidance, it helps break the cardiometabolic cycle and build sustainable long-term health beyond short-term weight loss.
From cholesterol tests and HbA1c for monitoring diabetes, to more specific markers like lipoprotein(a), or LP(a), patients are no longer waiting for symptoms or their GP's advice before seeking answers. Instead, they are becoming more proactive—taking charge of their health and accessing diagnostics that were once confined to clinical settings.
Statins are a mind boggling biological 'ruse'. When this medication is taken orally, it causes liver cells to become deficient in essential cholesterol, so they respond by increasing the number of cell surface LDL receptors, thereby enhancing their capacity to extract LDL particles from the blood, significantly lowering circulating LDL levels. Statins remain the most effective and well-known way that doctors can lower LDL levels to prevent or treat coronary heart disease.
Continuous glucose monitoring offers a valuable tool for anyone concerned with their long-term health, especially those with a family history of diabetes or other cardiovascular risk factors. Whether through self-monitoring or professional analysis such as our metabolic health assessment, CGMs can provide actionable insights that help individuals manage their glucose levels more effectively, ultimately contributing to a healthier, longer life. By understanding and managing your glucotype, optimising your diet and exercise, and taking steps to prevent prediabetes and diabetes, you can potentially avoid serious health conditions in the future.
N-of-1 medicine shifts the focus from population averages to personal biology. This blog series explores how individuals can run simple, safe self-experiments — using themselves as the control — to test plausible health hypotheses, track meaningful outcomes, and discover what genuinely improves their own health and wellbeing over time.
By Juliette Martin, Nutritional Therapist: Over the past year, a family of medications called GLP-1 agonists, often referred to as the ‘skinny jab’ has captured widespread media attention.
When blood sugar levels are consistently high, causing prediabetes and diabetes, the risk of conditions such as heart disease and type 2 diabetes increase in the long-term. It is easy to understand why the phenomenon of glucose spiking, where blood sugar levels surge and then fall back into the normal range after a meal, is also widely considered to be harmful.